Aurinia Pharmaceuticals Inc. Increase (Decrease) in Inventories
Aurinia Pharmaceuticals Inc. (AUPH) reported Increase (Decrease) in Inventories of -$539.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. increase (decrease) in inventories for the quarter ending 2026-06-30 was -$1.26M, a 508.77% decline year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in inventories for the quarter ending 2026-03-31 was $720.00K, a 89.67% decline year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in inventories for the quarter ending 2025-12-31 was $897.00K, a 74.51% increase year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in inventories for the quarter ending 2025-09-30 was -$1.71M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in inventories for fiscal 2025 was $6.46M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in inventories for fiscal 2024 was -$477.00K, a 103.01% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. increase (decrease) in inventories for fiscal 2023 was $15.87M, a 74.92% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. increase (decrease) in inventories for fiscal 2022 was $9.07M, a 60.74% increase from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$539.00K 10-Q · filed 2026-08-06 | $358.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $720.00K 10-Q · filed 2026-05-07 | $1.62M derived: sum of 2 quarters · filed 2026-05-07 | -$93.00K derived: sum of 3 quarters · filed 2026-05-07 | $215.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $897.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$813.00K derived: sum of 2 quarters · filed 2026-02-26 | -$505.00K derived: sum of 3 quarters · filed 2026-08-06 | $6.46M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.40M derived: sum of 2 quarters · filed 2026-08-06 | $5.57M 10-Q · filed 2025-11-04 | $6.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $308.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $7.28M 10-Q · filed 2026-08-06 | $7.79M derived: sum of 3 quarters · filed 2026-08-06 | $7.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.97M 10-Q · filed 2026-05-07 | $7.48M derived: sum of 2 quarters · filed 2026-05-07 | $7.34M derived: sum of 3 quarters · filed 2026-05-07 | $6.43M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $514.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $375.00K derived: sum of 2 quarters · filed 2026-02-26 | -$533.00K derived: sum of 3 quarters · filed 2026-02-26 | -$477.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$139.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.05M derived: sum of 2 quarters · filed 2025-11-04 | -$991.00K 10-Q · filed 2025-11-04 | $5.89M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$908.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$852.00K 10-Q · filed 2025-07-31 | $6.03M derived: sum of 3 quarters · filed 2026-02-26 | $6.61M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $56.00K 10-Q · filed 2025-05-12 | $6.94M derived: sum of 2 quarters · filed 2026-02-26 | $7.52M derived: sum of 3 quarters · filed 2026-02-26 | $8.93M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $6.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.47M derived: sum of 2 quarters · filed 2026-02-26 | $8.88M derived: sum of 3 quarters · filed 2026-02-26 | $15.87M 10-K · filed 2026-02-26 |
| 2023-09-30 | $581.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.99M derived: sum of 2 quarters · filed 2024-11-07 | $8.98M 10-Q · filed 2024-11-07 | $9.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $8.40M 10-Q · filed 2024-08-01 | $9.02M derived: sum of 3 quarters · filed 2025-02-27 | $9.52M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $6.99M 10-Q · filed 2024-05-02 | $7.61M derived: sum of 2 quarters · filed 2025-02-27 | $8.11M derived: sum of 3 quarters · filed 2025-02-27 | $9.13M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $614.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.12M derived: sum of 2 quarters · filed 2025-02-27 | $2.13M derived: sum of 3 quarters · filed 2025-02-27 | $9.07M 10-K · filed 2025-02-27 |
| 2022-09-30 | $505.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.52M derived: sum of 2 quarters · filed 2023-11-02 | $8.46M 10-Q · filed 2023-11-02 | $8.74M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $7.95M 10-Q · filed 2023-08-03 | $8.23M derived: sum of 3 quarters · filed 2024-02-15 | $10.15M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $6.94M 10-Q · filed 2023-05-04 | $7.22M derived: sum of 2 quarters · filed 2024-02-15 | $9.13M derived: sum of 3 quarters · filed 2024-02-15 | $10.57M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $278.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $2.19M derived: sum of 2 quarters · filed 2024-02-15 | $3.63M derived: sum of 3 quarters · filed 2024-02-15 | $5.64M 10-K · filed 2024-02-15 |
| 2021-09-30 | $1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $3.36M derived: sum of 2 quarters · filed 2022-11-03 | $5.37M 10-Q · filed 2022-11-03 | $18.82M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $3.45M 10-Q · filed 2022-08-04 | $16.91M derived: sum of 3 quarters · filed 2023-02-28 | $17.38M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $2.01M 10-Q · filed 2022-05-10 | $15.46M derived: sum of 2 quarters · filed 2023-02-28 | $15.94M derived: sum of 3 quarters · filed 2023-02-28 | $15.94M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $13.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $13.93M derived: sum of 2 quarters · filed 2023-02-28 | $13.93M derived: sum of 3 quarters · filed 2023-02-28 | $13.93M 10-K · filed 2023-02-28 |
| 2020-09-30 | $471.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $471.00K derived: sum of 2 quarters · filed 2021-11-03 | $471.00K 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |